Cargando…

Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells

BACKGROUND: The Gab2 docking protein acts as an important signal amplifier downstream of various growth factor receptors and Bcr-Abl, the driver of chronic myeloid leukaemia (CML). Despite the success of Bcr-Abl tyrosine kinase inhibitors (TKI) in the therapy of CML, TKI-resistance remains an unsolv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Halbach, Sebastian, Rigbolt, Kristoffer TG, Wöhrle, Franziska U, Diedrich, Britta, Gretzmeier, Christine, Brummer, Tilman, Dengjel, Jörn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640961/ https://www.ncbi.nlm.nih.gov/pubmed/23607741 http://dx.doi.org/10.1186/1478-811X-11-30

Ejemplares similares

Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
por: Halbach, Sebastian, et al.
Publicado: (2016)

Function, regulation and pathological roles of the Gab/DOS docking proteins
por: Wöhrle, Franziska U, et al.
Publicado: (2009)

Gab2 is Essential for Transformation by FLT3-ITD in Acute Myeloid Leukemia
por: Sies, Katharina, et al.
Publicado: (2019)

Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo
por: Spohr, Corinna, et al.
Publicado: (2021)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
por: Chuah, Charles, et al.
Publicado: (2009)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

Primary imatinib failure rescued by dasatinib and maintained by reintroduction of imatinib
por: Kumar, Rajiv, et al.
Publicado: (2017)

Involvement of mitochondrial dynamics in the segregation of mitochondrial matrix proteins during stationary phase mitophagy
por: Abeliovich, Hagai, et al.
Publicado: (2013)

Global remodelling of cellular microenvironment due to loss of collagen VII
por: Küttner, Victoria, et al.
Publicado: (2013)

Dasatinib/imatinib: Treatment failure: case report
Publicado: (2022)

Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment
por: Russo, D, et al.
Publicado: (2015)

Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
por: Conchon, Monika, et al.
Publicado: (2011)

Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia
por: Han, Jae Joon
Publicado: (2023)

Monocytic myeloid‐derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib
por: Giallongo, Cesarina, et al.
Publicado: (2017)

Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients
por: Chen, Li-Chia, et al.
Publicado: (2013)

The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia
por: Zhu, Yu, et al.
Publicado: (2016)

Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase
por: Yu, Lu, et al.
Publicado: (2019)

Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model
por: Lindström, H. Jonathan G., et al.
Publicado: (2022)

An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article
por: Wu, Bin, et al.
Publicado: (2017)

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
por: Uz, B., et al.
Publicado: (2011)

Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
por: Cortes, Jorge E., et al.
Publicado: (2016)

Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan
por: Chen, Teng-Chou, et al.
Publicado: (2013)

Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia
por: Banjar, Haneen, et al.
Publicado: (2017)

Patient Adherence and Persistence with Imatinib, Nilotinib, Dasatinib in Clinical Practice
por: Santoleri, Fiorenzo, et al.
Publicado: (2013)

Dasatinib‐induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review
por: Hsu, Chao‐Chin, et al.
Publicado: (2021)

A novel MCF-10A line allowing conditional oncogene expression in 3D culture
por: Herr, Ricarda, et al.
Publicado: (2011)

Phosphorylation Site Dynamics of Early T-cell Receptor Signaling
por: Chylek, Lily A., et al.
Publicado: (2014)

Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells
por: Liu, Juan, et al.
Publicado: (2016)

OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2014)

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
por: Ottmann, Oliver, et al.
Publicado: (2018)

Comparison of Dasatinib- and Imatinib-Related Cardiotoxic Adverse Events in Japanese Patients With Chronic Myeloid Leukemia and Gastrointestinal Stromal Tumor
por: Motokawa, Tetsufumi, et al.
Publicado: (2021)

Cost–utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia
por: Gordois, A, et al.
Publicado: (2003)

Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib
por: Bombeccari, Gian Paolo, et al.
Publicado: (2017)

Activation of ERK1/2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukaemia cells
por: Tsubaki, Masanobu, et al.
Publicado: (2023)

The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis
por: Mealing, Stuart, et al.
Publicado: (2013)

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
por: Hughes, T P, et al.
Publicado: (2015)

P675: IMATINIB THERAPY IN PREVIOUSLY UNTREATED CHRONIC MYELOID LEUKAEMIA PATIENTS WHO ACHIEVE MMR AFTER 12 MONTHS THERAPY WITH DASATINIB: A STRATEGY TO AVOID LONG TERM OFF TARGET TOXICITY
por: Pemberton, Lucy, et al.
Publicado: (2023)

Feasibility of treatment-free remission with generic imatinib: Results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study
por: Goni, Deepak, et al.
Publicado: (2023)

Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells
por: Sheng, Yaru, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_15a6jtffo180qc3o40s9m616mo